Hexavest Inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 476,038 shares of the biopharmaceutical company’s stock after acquiring an additional 5,449 shares during the period. Hexavest Inc.’s holdings in Gilead Sciences were worth $34,103,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of GILD. Welch Investments LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences in the 2nd quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the last quarter. 76.47% of the stock is owned by institutional investors.
Shares of Gilead Sciences, Inc. (GILD) opened at $81.55 on Friday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. The firm has a market cap of $106,500.00, a price-to-earnings ratio of 23.43, a PEG ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the prior year, the company posted $2.70 earnings per share. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year. research analysts anticipate that Gilead Sciences, Inc. will post 6.24 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.80%. Gilead Sciences’s dividend payout ratio is 59.77%.
GILD has been the subject of several research reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 19th. William Blair reissued a “buy” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Leerink Swann increased their price objective on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research note on Thursday, October 19th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $87.04.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares in the company, valued at $5,298,544.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP James R. Meyers sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 418,333 shares of company stock valued at $32,742,108. 1.30% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Stake Increased by Hexavest Inc.” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/16/gilead-sciences-inc-gild-stake-increased-by-hexavest-inc.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.